SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.

筛选耐受性佐剂以增强乳糜泻的抗原特异性免疫治疗。

• 批准号: 10933263
• 负责人: CHRISTINA CARGILL
• 金额: $ 59.99万
• 依托单位: QRONO, INC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2025-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933263
• 关键词: Adjuvant; Antigens; Autoimmune Diseases; Barley; Biological Assay; Celiac Disease; Cells; Chronic; Clinical; Contractor; Dendritic Cells; Evaluation; Gluten; Human; Immunotherapy; In Vitro; Interleukin-15; Macrophage; Patients; Peptides; Reproducibility; Rye cereal; Small Intestines; Testing; Wheat; adaptive immune response; design; screening

Celiac disease (CD) is a human chronic autoimmune disorder of the small intestine driven by adaptive immune responses to gluten peptides in wheat, barley, and rye. The contractor is targeting dendritic cells and macrophages to discovery new tolerogenic adjuvants which when paired with gluten antigens, may enable the first clinically viable immunotherapy for CD patients.

腹腔疾病（CD）是一种小肠的人类慢性自身免疫性疾病，由小麦，大麦和黑麦的适应性免疫反应驱动。承包商将树突状细胞和巨噬细胞靶向发现新的耐受性佐剂，当与麸质抗原配对时，可以为CD患者提供首次临床可行的免疫疗法。